Tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumors

Annals of Oncology

Volumn 24, Issue 2, 2013, Pages 322-328

  Massard, C ^a   Kramar, A ^b   Beyer, J ^c   Hartmann, J T ^d   Lorch, A ^e   Pico, J L ^a   Rosti, G ^f   Droz, J P ^g   Fizazi, K ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CENTRE OSCAR LAMBRET   (France)

^c VIVANTES KLINIKUM AM URBAN   (Germany)

^d UNIVERSITY OF KIEL   (Germany)

^e HEINRICH HEINE UNIVERSITY   (Germany)

^f OSPEDALE CA FONCELLO   (Italy)

^g CENTRE LÉON BÉRARD   (France)

Author keywords

Germ cell tumor; High dose chemotherapy; Prognosis; Relapse; Tumor marker

Indexed keywords

ALPHA FETOPROTEIN; CARBOPLATIN; CHORIONIC GONADOTROPIN; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; IFOSFAMIDE; TUMOR MARKER; VINBLASTINE;

ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NON SEMINOMATOUS GERMINOMA; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION;

EID: 84873740061     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds504     Document Type: Article

References (19)

1. Krege S, Beyer J, Souchon R et al European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol 2008; 53 (3): 478-496.
2. Feldman DR, Bosl GJ, Sheinfeld J et al Medical treatment of advanced testicular cancer. JAMA 2008; 299(6): 672-684.
3. Pico JL, Rosti G, Kramar A et al A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol 2005; 16(7): 1152-1159.
4. Lorch A, Kollmannsberger C, Hartmann JT et al Single versus sequential highdose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group. J Clin Oncol 2007; 25(19): 2778-2784.
5. Einhorn LH, Williams SD, Chamness A et al High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med 2007; 357(4): 340-348.
6. Feldman DR, Sheinfeld J, Bajorin DF et al TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. J Clin Oncol 2010; 28(10): 1706-1713.
7. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997; 15(2): 594-660.
8. Mazumdar M, Bajorin DF, Bacik J et al Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy. J Clin Oncol 2001; 19(9): 2534-2541.
9. Fizazi K, Culine S, Kramar A et al Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J Clin Oncol 2004; 22(19): 3868-3876. Epub 2004 Aug 9.
10. Motzer RJ, Nichols CJ, Margolin KA et al Phase III randomized trial of conventionaldose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poorprognosis metastatic germ cell tumors. J Clin Oncol 2007; 25(3): 247-256.
11. Fizazi K, Culine S, Droz JP et al Primary mediastinal nonseminomatous germ cell tumors: results of modern therapy including cisplatin-based chemotherapy. J Clin Oncol 1998; 16(2): 725-732.
12. Bokemeyer C, Nichols CR, Droz JP et al Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis. J Clin Oncol 2002; 20(7): 1864-1873.
13. Hartmann JT, Einhorn L, Nichols CR et al Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: results of an international multicenter analysis. J Clin Oncol 2001; 19(6): 1641-1648.
14. Hartmann JT, Nichols CR, Droz JP et al Prognostic variables for response and outcome in patients with extragonadal germ-cell tumors. Ann Oncol 2002; 13(7): 1017-1028.
15. Kondagunta GV, Bacik J, Donadio A et al Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol 2005; 23(27): 6549-6555.
16. Kondagunta GV, Bacik J, Sheinfeld J et al Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors. J Clin Oncol 2007; 25(1): 85-90.
17. Fizazi K, Gravis G, Flechon A et al A prospective multicenter GETUG phase II trial of gemcitabine, cisplatin, and ifosfamide (GIP) in patients with relapsed metastatic germ-cell tumors (GCT). Abstract 8690, ESMO Meeting 2010.
18. Lotz J, Selle F, Fizazi K et al A phase II trial of high-dose chemotherapy (HDCT) supported by haematopoietic stem cell transplantation (HSCT) in patients (pts) with disseminated germ-cell tumors (GCTs) failing chemotherapy and with adverse prognostic factors: The TAXIF II protocol. J Clin Oncol 27:15s, 2009 (suppl; abstr 5028).
19. Feldman DR, Huddart R, Hall E et al Is high dose therapy superior to conventional dose therapy as initial treatment for relapsed germ cell tumors? The TIGER Trial. J Cancer 2011; 2: 374-377. Epub 2011 Jul 1.